



Cut-Off Value of Serum Uric Acid for Development of Gout Disease in Patients with Multiple Co-Morbidities

Firdevs Ulutaş¹ , Aslı Bozdemir² , Nevzat Atalay Çelikyürek³ , Canan Albayrak Yaşar¹ , Veli Çobankara¹ 

¹Division of Rheumatology, Department of Internal Medicine, Pamukkale University Faculty of Medicine, Denizli, Turkey, ²Department of Internal Medicine, Pamukkale University Faculty of Medicine, Denizli, Turkey, ³Department of Public Health, Pamukkale University Faculty of Medicine, Denizli, Turkey

ABSTRACT

Objective: This study aimed to determine the association between hyperuricemia, comorbid diseases and risk of developing gout disease in a Turkish population in a long follow-up period. **Methods:** A total of 2000 Turkish adults were cross-sectionally analysed for serum urate levels in 2009 at the Pamukkale University Faculty of Medicine. All patients on regular follow-up at our tertiary health center (n=1322) were included in this study. Demographic features (age and gender), comorbid clinical conditions, and medication use were noted. The risk of developing gout and the determinant factors were investigated. Multivariate logistic regression analysis was performed to analyse causative effects of factors while receiver operating characteristic (ROC) curve analysis was used to identify optimal cut-off values of uric acid level for predicting the development of gout. **Results:** Among 1322 patients, the mean age was 56.9 (SD:14.68) years. 57.3% (n=758) of the patients were female. The most common co-morbid disease was chronic kidney disease (581, 43%), followed by hypertension (522, 39.4%). Gout developed in 25 patients (1.8%). Gout development risk and presence of all the above comorbidities were significantly higher in patients with serum urate ≥ 7 mg/dl compared with < 7 mg/dl. Male gender and not using urate lowering drugs were the main risk factors for developing gout disease. ROC analysis of serum uric acid levels identified a cut-off value of > 7 (AUC: 0.776, sensitivity 86.96%, specificity 66.74%). **Conclusion:** There is still a dilemma concerning the culprit effects of both comorbidities and hyperuricemia on the risk of developing gout disease.

Mediterr J Rheumatol 2021;32(3):243-8

<https://doi.org/10.31138/mjr.32.3.243>

Article Submitted: 12 Dec 2020; Revised Form: 13 Jan 2021; Article Accepted: 20 Jun 2021; Available Online: 30 Sep 2021

Keywords: hyperuricemia, gout, co-morbid disease, cut-off

Corresponding Author:

Firdevs Ulutaş
Division of Rheumatology,
Department of Internal Medicine
Pamukkale University Faculty of Medicine
Çamlaraltı Pamukkale Üniv. Hastane Yolu
20070 Kınıklı/Pamukkale/Denizli, Turkey
Tel: +90 530 094 4632
E-mail: firdevsulutas1014@gmail.com

INTRODUCTION

Gout is an increasingly common chronic inflammatory disease that manifests as flares of acute inflammatory arthritis and/or clinical manifestations of chronic urate crystal deposition.¹ A population-based epidemiological study revealed the estimated prevalence of gout as 0.31% for subjects ≥ 20 years of age,

and 0.72% for subjects ≥ 40 years of age in an urban area of Turkey.² The burden of gout has increased in the last decades in industrialised countries. This increased incidence is attributed to changes in lifestyle, to related comorbidities including obesity and metabolic syndrome and to prolonged lifespan.³

The normal reference range of serum uric acid is determined by evaluating its variable levels among healthy subjects who have no clinical evidence of hyperuricemia. The cut-off value of hyperuricemia varies due to sex-specific effects (sex–diet and sex–gene interactions) in women and men.⁴ Although there is no well-defined accepted definition of hyperuricemia today, exact evidence of a relationship between degree of hyperuricemia and risk of developing gout has been reported.⁵ Champion EW et al. investigated the relationship between serum uric acid and the development of gout in 2046 initially healthy men for 15 years. They found a positive correlation and that the cumulative incidence of gout with serum urate levels of 9 mg/dL or greater was 22 percent after five years.⁶ Animal models and cell culture studies have shown that hyperuricemia also plays a main culprit role in the underlying pathophysiological mechanism in many “cardio-nephro-metabolic” disorders without the deposition of monosodium urate crystals.⁷ For example, increased serum uric acid leads to high blood pressure, initially via direct action on smooth muscle and vascular endothelial cells, then plays a role as an independent risk factor for poor cardiovascular prognosis.⁸

Many observational studies have also noted that hyperuricemia alone is not a sufficient risk factor for development of gout. These observational studies showed 4-5 co-morbidity clusters in gout patients.⁹ In addition, Mendelian randomisation studies showed new genome-wide significant loci associated with serum uric acid concentration.¹⁰ Several common comorbidities also have a higher prevalence among patients with asymptomatic hyperuricemia. Therefore, the causal relationships between gout, relevant comorbidities and hyperuricemia are quite complex and their interrelationships are not yet fully understood due to heterogeneous study design and varied populations. There has been no observational study that investigated the association between hyperuricemia, relevant comorbidities and development of gout with long term follow-up in the Turkish population. We aimed to determine the risk cut-off value of serum uric acid for development of gout in patients with multiple comorbidities.

MATERIALS AND METHODS

This observational cohort study was designed to quantify the risk of developing gout disease in patients with hyperuricemia and multiple co-morbidities among 2000 Turkish adults whose serum uric acid levels were cross-sectionally analysed in 2009. All of the patients (n=1322) enrolled in this study were on regular follow-up for eleven years in our tertiary health center.

Inclusion criteria were defined as: having regular follow-up for the time period studied. Exclusion criteria were defined as: having no sufficient medical data due to irregular follow-up, death of the patient in the follow-up

period, or having gout diagnosed initially.

835 patients with baseline levels of SUA<7.0mg/dl and 487 patients with SUA≥7 mg/dl were included. We called all of the subjects by telephone and questioned them on complaints of arthralgia in any joint, morning stiffness, or tophi. All of the suspected individuals were invited to the hospital for physical examination and repeated laboratory measurements including serum uric acid and acute phase reactants. Gout was clinically diagnosed by the same rheumatologist based on history and physical examination according to the current clinical classification criteria.¹¹ For patients who were diagnosed with gout arthritis, family history, alcohol consumption, diuretic use, urate lowering drug use and obesity were carefully investigated.

Demographic features (age and gender), comorbid clinical conditions including hypertension, diabetes mellitus, hyperlipidemia, chronic kidney disease, nephrolithiasis and cardiovascular disease, and medication use were noted exactly. Mean systolic blood pressure ≥140 mmHg or mean diastolic blood pressure ≥90 mmHg, fasting serum glucose levels ≥126 mg/dl, total cholesterol ≥200 mg/dl or low-density cholesterol (LDL-C) ≥130 mg/dl were accepted as positive cut-off values for hypertension, diabetes mellitus, and hyperlipidemia, respectively, whereas history of coronary artery disease, heart failure, and/or using relevant drugs defined cardiovascular disease. Having treatment for cardiovascular disease was also accepted as having this co-morbidity. Individuals who had an estimated-glomerular filtration rate (e-GFR) below 60 mL/min per 1.73 m² were accepted as having chronic kidney disease. For defining nephrolithiasis, presence of positive imaging was accepted.

The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a prior approval by the local Ethics Committee of our health center. Informed consent forms were obtained from patients in this study.

Statistical Analysis

For statistical analysis, SPSS 17.0 (SPSS Inc. Released 2008. SPSS Statistics for Windows, Version 17.0. Chicago: SPSS Inc.) was used. Descriptive statistics are given as mean ± standard deviation for continuous variables. Numbers and percentages are used for categorical variables. Normality of numerical variables was checked with Kolmogorov-Smirnov and Shapiro-Wilk tests. Mann Whitney U test was used for comparison of two independent groups and Kruskal-Wallis test was used for comparison of three or more independent groups. For comparison of differences between categorical variables, Chi-Square test was used. Multivariate logistic regression analyses were performed to analyse factors that had an impact on the development of gout. Variables were adjusted for age and sex. Receiver operating character-

istic (ROC) curve analysis was used to determine optimal cut-off values of uric acid level for predicting the development of gout. Area under curve (AUC) was calculated using the DeLong method (MedCalc Statistical Software Trial version-MedCalc Software bvba, Ostend, Belgium; <http://www.medcalc.org>; 2015) with Youden's index and a confidence interval of 95%. $p < .05$ (2-sided) was considered statistically significant in all statistical analyses.

RESULTS

A total of 1322 patients were enrolled in this study. The mean age was 56.9 years (SD:14.68) in the whole study group. 57.3% (n=758) of patients were female. The most common comorbid disease was chronic kidney disease (CKD) (n=581, 43%), followed by hypertension (n=522, 39.4%), hyperlipidemia (n=488, 36.8%), diabetes mellitus (n=467, 35.3%), cardiovascular disease (n=238, 18%), and nephrolithiasis (n=44, 3.3%). 7.6% of patients (n=101) were initially on urate lowering therapy (**Table 1**). Gout developed in 25 patients (1.8%). 14 (56%) patients diagnosed with gout initially presented with podagra joint, and a family history of gout was present for 7 (28%) patients (**Table 1**).

Gout development risk, male dominance, presence of all the above comorbidities, and using ULDs were significantly higher in patients with serum urate ≥ 7 mg/dl compared with < 7 mg/dl (**Table 2**). The possibility of diagnosis with CKD, NL and CVD was significantly higher in patients with SUA ≥ 9 mg/dl compared with lower serum urate levels (**Table 3**). Male gender and not using urate lowering drugs were the main risk factors for developing gout disease (**Table 4**). There was no statistically significant difference between patients with and without gout based on the presence of concurrent comorbidities, except male predominance for gout patients. ROC analysis of serum uric acid levels revealed a cut-off value of > 7 (AUC: 0.776, sensitivity 86.96%, specificity 66.74%) (**Table 5, Figure 1**).

DISCUSSION

We found that all of the comorbidities including CKD, HT, HL, NL, DM, CVD, and risk of developing gout were more commonly seen in patients having SUA ≥ 7 mg/dl compared with < 7 mg/dl. The risk cut-off value for development of gout was defined as > 7 mg/dl for patients with multiple co-morbidities. The presence of CKD, NL or CVD had a high prevalence among patients with SUA ≥ 9 mg/dl, even if they were more commonly treated with ULDs. Firstly, we noticed again that hyperuricemia was also an important etiological culprit factor for common morbidities such as cardiovascular disease, chronic kidney disease, and NL, similar to recent experimental and epidemiologic studies.¹² Secondly, this result reinforced our opinion of the real beneficial effects of ULDs on insulin resistance, hypertension, and development of

Table 1. Patient characteristics in the whole study group (n=1322).

Patient characteristics	n (%)
Serum uric acid (mg/dl)	
7mg/dl \geq	487 (36.8)
7mg/dl $<$	835 (63.2)
Levels of uric acid (mg/dl)	
7mg/dl $<$	835 (63.2)
7mg/dl -7.9 mg/dl	270 (20.4)
8mg/dl -8.9 mg/dl	146 (11)
9mg/dl \geq	71 (5.4)
Age	Mean: 56.93 (SD: 14.68)
Gender	
Male	564 (42.7)
Female	758 (57.3)
Chronic kidney disease	581 (43.9)
Diabetes mellitus	467 (35.3)
Hyperlipidaemia	488 (36.8)
Hypertension	522 (39.4)
Nephrolithiasis	44 (3.3)
Cardiovascular disease	238 (18)
Alcohol use	14 (1.1)
Urate lowering drugs (Allopurinol:100, Febuxostat:1)	101 (7.6)
Gout development in whole group	25 (1.8)
Podagra presentation in gout	14 (56)
Family history in gout	7 (28)

gout since a few studies have shown that hyperuricemic control with the available drugs may ameliorate some of these related conditions.¹³ Allopurinol-treated individuals with asymptomatic hyperuricemia showed improvement in insulin resistance, fasting blood glucose, HOMA-IR index and serum high-sensitivity C-reactive protein.¹⁴ It was also shown that allopurinol alleviates hypertension and proteinuria in patients with metabolic syndrome.¹⁵ In addition, ULDs prevent attacks in high risk patients who suffer from gout.

Öztürk MA et al. showed that the most common clinical comorbidity was hypertension (in 53.5% of patients) in patients with gout in Turkey.¹⁶ In a population cohort, hypertension, chronic kidney disease, obesity, diabetes mellitus, nephrolithiasis, and heart failure were substantially higher in patients with gout than without gout, and the overall comorbidity prevalence was highest when

Table 2. Comparison of patient characteristics between groups determined by serum uric acid levels (UA \geq 7mg/dl or UA <7mg/dl).

	UA \geq 7mg/dl n (%)	UA <7mg/dln (%)	p value
Gender			<0.001
Male	325 (66.7)	239 (28.6)	
Female	162 (33.3)	596 (71.4)	
CKD	342 (70.2)	239 (28.6)	<0.001
DM	249 (51.1)	218 (26.1)	<0.001
HL	211 (43.3)	277 (33.2)	<0.001
HT	303 (62.2)	219 (26.2)	<0.001
NL	29 (6)	15 (1.8)	<0.001
CVD	132 (27.1)	106 (12.7)	<0.001
Alcohol	9 (1.8)	5 (0.6)	0.063
Gout development	21 (4.3)	4 (0.5)	<0.001
ULDs			<0.001
Allopurinol	89 (18.3)	11 (1.3)	
Febuxostat	1 (0.2)	0 (0)	

UA: uric acid; CKD: chronic kidney disease; DM: diabetes mellitus, HL: hyperlipidaemia; HT: hypertension; NL: nephrolithiasis; CVD: cardiovascular disease, ULDs: urate lowering drugs.

Table 3. Comparison of patients with serum uric acid levels above UA \geq 7mg/dl in three subgroups.

		UA \geq 7mg/dl – 7.9 mg/dl (n, %)	UA \geq 8 mg/dl – 8.9 mg/dl (n, %)	UA \geq 9 mg/dl (n, %)	P value
Gender	Male	178 (65.9)	99 (67.8)	48 (67.6)	0,914
	Female	92 (34.1)	47 (32.2)		
CKD		174 (64.4)	114 (78.1)	54 (76.1)	0.008
DM		147 (54.4)	69 (47.3)	33 (46.5)	0.262
HL		112 (41.5)	61 (41.8)	38 (53.5)	0.172
HT		169 (62.6)	86 (58.9)	48 (67.6)	0.455
NL		15 (5.6)	4 (2.7)	10 (14.1)	0.004
CVD		63 (23.3)	44 (30.1)	25 (35.2)	0.083
Alcohol		4 (1.5)	3 (2.1)	2 (2.8)	0.740
Gout		9 (3.3)	8 (5.5)	4 (5.6)	0.494
ULDs	Allopurinol	40 (14.8)	22 (15.1)	27 (38)	<0.001
	Febuxostate	0 (0)	0 (0)	1 (1.4)	

UA: uric acid; CKD: chronic kidney disease; DM: diabetes mellitus; HL: hyperlipidaemia; HT: hypertension; NL: nephrolithiasis; CVD: cardiovascular disease.

gout and hyperuricemia were present together.¹⁷ There was no statistical significance for the presence of comorbidities in gout and non-gout patients but the likelihood of having DM, CKD, or HL was higher in gout patients. This can be explained by the very limited number of gout patients in the whole cohort.

Data from the United States National Health and Nutrition Examination Survey (NHANES) 2007–2008 study showed a gout prevalence of 3.9% (5.9% for men; 2.0% for women), but a higher hyperuricemia prevalence of 21.4% (21.2% for men; 21.6% for women).¹⁷ The prevalence of hyperuricemia has also risen steadily over the

Table 4. Odds ratio between variables.

	Adjusted OR	95% CI		p value
Age	1.027	0.997	1.058	0.074
Male Gender	6.363	2.149	18.840	0.001
CKD	0.704	0.299	1.658	0.422
DM	1.448	0.620	3.383	0.392
HL	1.357	0.587	3.137	0.475
HT	0.497	0.198	1.248	0.136
NL	2.194	0.482	9.993	0.310
CVD	1.313	0.503	3.427	0.578
Not using ULDs	29.772	11.238	78.870	<0.001

Odds ratio was adjusted for age and sex.

UA: uric acid; CKD: chronic kidney disease; DM: diabetes mellitus; HL: hyperlipidaemia; HT: hypertension; NL: nephrolithiasis; CVD: cardiovascular disease; ULDs: urate lowering drugs.

Table 5. Presence of variables in gout and non-gout patients.

Gout (n, %) (n=25)		Presence of gout disease		P value
		Non-gout (n, %) (n=1297)		
Gender	Male	20 (80)	544 (41)	<0.001
	Female	5 (20)	753 (58)	
CKD		10 (40)	571 (44)	1.000
DM		12 (48)	455 (35)	0.137
HL		11 (44)	477 (36.7)	0.381
HT		8 (32)	514 (39.6)	0.802
NL		4 (16)	45 (3.4)	0.177
CVD		7 (28)	231 (17.8)	0.163
Alcohol		0 (0)	14 (1.1)	1.000

CKD: chronic kidney disease; DM: diabetes mellitus; HL: hyperlipidaemia; HT: hypertension; NL: nephrolithiasis; CVD: cardiovascular disease.

last decades, as has gout.¹⁸ Ultimately, gout developed in a minority of patients with hyperuricemia, as shown in our study. Other reasons for this result may be explained by female dominance in the whole cohort and being on treatment with ULDs initially. Today most of the gene studies have been focused on genetic markers of susceptibility to gout related to renal excretion of uric acid.¹⁹ Genome-wide association studies (GWAS) have also identified the role of the kidneys, gut and liver as sites of urate regulation. In addition, genetic variants that predict

responsiveness to therapies are still being researched. As a result, comorbidities and hyperuricemia have been identified as additional culprit factors for the development of gout in patients with genetic susceptibility.²⁰

Currently, asymptomatic hyperuricemia alone is not an indication for urate lowering therapy. There have not been enough randomised placebo-controlled trials that assessed the benefits of treating in the asymptomatic phase. Masayuki Hakoda et al have noticed that the prevalence of male patients with asymptomatic hyperuricemia under ULDs was significantly increased (2.14%) in recent years (during 2010-2014), and was higher than that of gout in Japan.²¹ In our study, the presence of gout disease was similar in the three subgroups among patients with serum urate ≥ 7 mg/dl. This condition may be explained by the higher rate of patients on ULDs in the subgroup with serum urate ≥ 9 mg/dl.

A few limitations were present in this study. First, this cross-sectional observational study could not reveal a clear causal relationship. Patients on initial ULDs treatment were included, which led to heterogeneity of patients in the groups.

CONCLUSION

Although the cut-off value of serum uric acid was >7 for risk of gout development in patients with multiple comorbidities, there is still a dilemma as to which serum uric acid level plays a significant role in developing gout. Also, culprit effects of each comorbidity are not well defined due to cluster effects. We hope future studies, especially related to genome-wide associations and culprit factors for gout disease, will enable us to be better informed.




Figure 1. ROC analysis of blood uric acid levels for the development of gout (The cut-off value of uric acid was defined as >7 sensitivity 86.96%, specificity 66.74%, [0.752 – 0.798,95% CI])
ROC: receiver operating curve; AUC: area under curve; CI: confidence interval.

AUTHOR CONTRIBUTIONS

All authors equally contributed to this manuscript and approved final version for publication.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

1. Richette P, Bardin T. Gout. *Lancet* 2010;375:318-28.
2. Biriik M, Gurler O, Akar S, Sari I, Onen F, Akkoc N. The prevalence of gout in an urban area of Izmir, Turkey: a population-based epidemiological study. *Int J Clin Pract* 2014;68:775-82.
3. Perez-Ruiz F, Dalbeth N, Bardin T. A review of uric acid, crystal deposition disease, and gout. *Adv Ther* 2015;32:31-41.
4. Soysal P. Comment on "Serum uric acid is associated with better executive function in men but not in women: Baseline assessment of the ELSA-Brasil study". *Exp Gerontol* 2017;1:96-9.
5. Hall AP, Barry PE, Dawber TR, Mc Namara PM. Epidemiology of gout and hyperuricemia. A long-term population study. *Am J Med* 1967;42:27-37.
6. Champion EW, Glynn RJ, Delabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. *Am J Med* 1987;82:421-6.
7. Johnson R, Bakris G, Borghi C, Chonchol M, Feldman D, Lanaspas M, et al. Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. *Am J Kidney Dis* 2018;71:851-65.
8. Feig D, Mazzali M, Kang D, Nakagawa T, Price K, Kannelis J, et al. Serum uric acid: a risk factor and a target for treatment? *J Am Soc Nephrol* 2006;17(4 Suppl 2):S69-73.

9. Bevis M, Blagojevic-Bucknall M, Mallen C, Hider S, Roddy E. Comorbidity clusters in people with gout: an observational cohort study with linked medical record review. *Rheumatology (Oxford)* 2018;57:1358-63.
10. Köttgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. *Nat Genet* 2013;45:145-54.
11. Neogi T, Jansen TL, Dalbeth N, Fransen J, Scuhmacher R, Berendsen D, et al. Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Ann Rheum Dis* 2015;74:1789-98.
12. Majdan M, Borys O. Gout and comorbidities associated with hyperuricemia. *Ann Acad Med Stetin* 2010;56(Suppl 1):34-9.
13. Karis E, Crittenden DB, Pillinger MH. Hyperuricemia, gout, and related comorbidities: cause and effect on a two-way Street. *South Med J* 2014;107:235-41.
14. Takir M, Kostek O, Ozkok A, Elcioglu OC, Bakan A, Erek A, et al. Lowering Uric Acid With Allopurinol Improves Insulin Resistance and Systemic Inflammation in Asymptomatic Hyperuricemia. *J Investig Med* 2015;63:924-9.
15. El-bassossy HM, Shaltout HA. Allopurinol alleviates hypertension and proteinuria in high fructose, high salt and high fat induced model of metabolic syndrome. *Transl Res* 2015;165:621-30.
16. Öztürk MA, Kaya A, Şenel S, Dönmez S, Balkarlı A, Çobankara V, et al. Demographic and clinical features of gout patients in Turkey: a multicenter study. *Rheumatol Int* 2013;33:847-52.
17. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. *Am J Med* 2012;125:679-87.e1.
18. Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. *Am J Transl Res* 2020;12:3167-81.
19. Riches P, Wright AF, Ralston SH. Recent insights into the pathogenesis of hyperuricaemia and gout. *Hum Mol Genet* 2009;18:R177-84.
20. Major TJ, Dalbeth M, Stahl EA, Merriman TR. An update on the genetics of hyperuricaemia and gout. *Nat Rev Rheumatol* 2018;14:341-53.
21. Hakoda M, Kasagi F. Increasing trend of asymptomatic hyperuricemia under treatment with urate-lowering drugs in Japan. *Mod Rheumatol* 2019;29:880-4.